(Q35065516)

6 August 2017

1 reference

title

Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? (English)

1 reference

6 August 2017

Gozewijn D Laverman

1

1 reference

PubMed ID

12584664

6 August 2017

Dick de Zeeuw

series ordinal

2

1 reference

PubMed ID

12584664

6 August 2017

Gerjan Navis

series ordinal

3

1 reference

6 August 2017

1 December 2002

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

6 August 2017

1 reference

6 August 2017

3

1 reference

6 August 2017

4

1 reference

6 August 2017

205-213

1 reference

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

6 August 2017

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Progression, remission, regression of chronic renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Slowing the progression of renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition?

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Serum immunoreactive-leptin concentrations in normal-weight and obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments]

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

21 January 2018

Leptin and renal disease

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Pharmacogenomics: unlocking the human genome for better drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Familial factors in the antihypertensive response to lisinopril

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Synergistic effect of α-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Baroreflex buffering and susceptibility to vasoactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Genetic influences on baroreflex function in normal twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

ACE genotype and ACE inhibitor response in kidney disease: a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Add-on angiotensin receptor blockade with maximized ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Dual renin-angiotensin system blockade at optimal doses for proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Effect of combining ACE inhibitor and statin in severe experimental nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Remission Achieved in Chronic Nephropathy by a Multidrug Approach Targeted at Urinary Protein Excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.042

21 January 2018

Identifiers

DOI

10.3317/JRAAS.2002.042

1 reference

6 August 2017

1 reference

PubMed ID

12584664